Alok Rustogi, MD
Adolescent Medicine · Potomac Falls, VANPI 1730116575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,160, 2.3 times the $952 reported in 2019.
Across 414 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$1K
- Amgen$648
- Sanofi-aventis U.S. LLC$479
- Bayer$442
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$1722%
- Food & beverage$8,73097%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,574 |
| AbbVie(2 entities) | 38 | $1,235 |
| Novo Nordisk | 64 | $1,166 |
| Amgen | 32 | $648 |
| Sanofi-aventis U.S. LLC | 24 | $479 |
| Bayer | 23 | $442 |
| GSK | 16 | $428 |
| Pfizer | 20 | $390 |
| Lilly USA, LLC | 16 | $333 |
| Johnson & Johnson | 14 | $318 |
| Sunovion Pharmaceuticals Inc. | 13 | $212 |
| Sumitomo Pharma America, Inc. | 9 | $188 |
| Astellas Pharma US Inc | 5 | $182 |
| Boehringer Ingelheim | 6 | $125 |
| Amarin Pharma, Inc. | 7 | $120 |
| Kowa Pharmaceuticals America, Inc. | 6 | $96 |
| Amneal Pharmaceuticals LLC | 4 | $93 |
| Novartis | 5 | $92 |
| Merck | 6 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Agios Pharmaceuticals, Inc. | 3 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $74 |
| Eisai Inc. | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $50 |
| Insulet Corporation | 2 | $47 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Exact Sciences | 2 | $36 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,994 in reported general payments places this provider in the 85th percentile of 49 adolescent medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 245 | $134,751 |
| OzempicSemaglutide | 69 | $102,515 |
| MounjaroTirzepatide | 65 | $76,980 |
| FarxigaDapagliflozin Propanediol | 51 | $63,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $54,008 |
| JanuviaSitagliptin Phosphate | 37 | $48,681 |
| LinzessLinaclotide | 30 | $41,820 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $40,095 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $36,953 |
| RybelsusSemaglutide | 15 | $33,468 |
| Repatha SureclickEvolocumab | 22 | $25,352 |
| XareltoRivaroxaban | 24 | $23,720 |
| KerendiaFinerenone | 15 | $21,773 |
| TrulicityDulaglutide | 13 | $19,463 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $18,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,166 | $135,98384 claims |
| PfizerEliquis | $390 | $134,751245 claims |
| Lilly USA, LLCMounjaro, Trulicity | $333 | $96,44378 claims |
| MerckJanuvia, Janumet | $91 | $67,40955 claims |
| AstraZenecaFarxiga | $1,574 | $63,74151 claims |
| AbbVieLinzess, Restasis, Synthroid | $1,235 | $56,69080 claims |
| GSKTrelegy Ellipta | $428 | $54,00844 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $479 | $36,95337 claims |
| Johnson & JohnsonXarelto | $318 | $23,72024 claims |
| BayerKerendia | $442 | $21,77315 claims |
| Boehringer IngelheimJardiance | $125 | $17,65518 claims |
| NovartisEntresto | $92 | $13,81219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 adolescent medicine providers in Virginia.
Other adolescent medicine in Potomac Falls
- John ZacharyMidlothian$301K
- George BrightMidlothian$284K
- Robert ShayneChester$165K
- Kerri SteeleChester$164K
- Mark PolanshekChester$164K
- Kevin CampbellChester$164K
- Michele BurgetMidlothian$133K
- Peter HeymanRichmond$3K
- Melani de SilvaRichmond$3K
- Charles TerryRichmond$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.